Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.41 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4158001 | 1.00 | MAPK14 (0.44) | MAPK14CYP11B2CYP19A1CYP11B1HTR2B | |
| SCHEMBL4045716 | 0.91 | CYP11B2 (0.46) | CYP11B2CYP19A1CYP11B1SRD5A1PARP1 | |
| SCHEMBL4153615 | 0.90 | PARP1 (0.39) | MAPK14HTR2BSRD5A1NR3C2ALDH1A1 | |
| SCHEMBL4153618 | 0.90 | PARP1 (0.39) | MAPK14HTR2BSRD5A1NR3C2ALDH1A1 | |
| SCHEMBL27913341 | 0.84 | SRD5A1 (0.52) | MAPK14CYP11B2CYP19A1CYP11B1SRD5A1 | |
| SCHEMBL4040169 | 0.84 | CES1 (0.50) | CYP11B2CYP19A1CYP11B1HTR2BALDH1A1 | |
| SCHEMBL4038027 | 0.81 | MAPK14 (0.48) | MAPK14CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL4042550 | 0.81 | MAPK14 (0.48) | MAPK14CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL4038030 | 0.81 | MAPK14 (0.48) | MAPK14CYP11B2CYP19A1CYP11B1 | |
| SCHEMBL4036595 | 0.80 | HTT (0.44) | CYP11B2CYP19A1CYP11B1HTR2BSRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | COGHLAN MICHAEL JOSEPH | 2009-06-11 | — | — | US | disclosed |
| US-7411072-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2008-08-12 | — | — | US | disclosed |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY | 2006-03-23 | — | — | US | disclosed |
| EP-1519915-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-04-06 | — | — | EP | disclosed |
| WO-2004052847-A2 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149445-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | NR5A1, NR3C2, NR3C1 | MAPK14 1472/4885CYP11B2 15/4885CYP19A1 44/4885 |
| US-20060063759-A1 | Tricyclic steroid hormone nuclear receptor modulators | NR5A1, NR3C2, NR3C1 | MAPK14 1545/4885CYP11B2 17/4885CYP19A1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.